search
Back to results

Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock

Primary Purpose

Ketamine, Fentanyl, Septic Shock

Status
Not yet recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Ketamine
Fentanyl
Sponsored by
Cairo University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Ketamine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult (>18 years) patients. With septic shock on vasopressor therapy Mechanically ventilated Need for sedation Exclusion Criteria: Hemodynamic instability (MAP <65 mmHg) despite appropriate volume replacement and vasopressor therapy Noradrenaline infusion rate <0.05 mcg/kg/min Poor cardiac window on the ultrasound. Known allergy to study drugs Neurocritical patients with signs of increased intracranial tension

Sites / Locations

  • Ahmed Mohamed Hasanin

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Ketamine group

Fentanyl group

Arm Description

bolus of sedation for resuming sedation after sedation vacation

bolus of sedation for resuming sedation after sedation vacation

Outcomes

Primary Outcome Measures

6-minutes Delta CO%
percentage of change at 6 min after drug administration in relation to the baseline measurement

Secondary Outcome Measures

Delta CO%
percentage of change at each time point after drug administration in relation to the baseline measurement
heart rate
beat per minute
mean blood pressure
mmHg
norepinephrine dose
mcg/kg/min

Full Information

First Posted
July 14, 2023
Last Updated
July 14, 2023
Sponsor
Cairo University
search

1. Study Identification

Unique Protocol Identification Number
NCT05957302
Brief Title
Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock
Official Title
Comparing the Hemodynamic Effects of Bolus of Ketamine and Fentanyl in Patients With Septic Shock: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Ketamine is a commonly used drug for sedation and induction of anesthesia in patients with shock and/or cardiac dysfunction. Ketamine is characterized by its cardiovascular stimulatory effect due to increase release of endogenous catecholamines. On the other hand, laboratory data on the isolated human myofibers suggest that ketamine had a direct myocardial depressive effect; accordingly, many experts believe that ketamine might have a negative hemodynamic effect in catecholamine depleted patients such as critically ill patients. In critically ill patients, there are contradicting results for the effect of ketamine on the hemodynamic profile and there is paucity of clinical data about the effect of ketamine on cardiac contractility and cardiac output (CO). Cardiac output is the primary determinant of global oxygen delivery to organs and maintaining stable CO in critically ill patients is at most importance to avoid further organ damage in such patients. Therefore, this study is designed to evaluate the effect a single bolus of ketamine on CO in patients with septic shock in comparison to fentanyl bolus.
Detailed Description
Patients meeting the inclusion criteria will receive the study drug according to the randomization, if a bolus of sedation is required for resuming sedation after sedation vacation. All patients will be monitored by 5-lead electrocardiogram, pulse oximetry, and noninvasive blood pressure. Hypotension defined as mean arterial pressure < 65 mmHg and will be managed by increasing the norepinephrine infusion rate by 20%. Bedside echocardiography will be used to measure the cardiac output by an experienced physician who is not aware of the nature of the study drug. The left ventricular outflow diameter (LVOT) will be measured in the parasternal long-axis view. Then velocity time integral (VTI) will be measured from the apical five-chamber view. The average of three VTI readings will be calculated. The cardiac output will be calculated by the equation: CO = π X (LVOT diameter/2) X VTI X heart rate Delta CO% will be calculated as percentage of change at each time point in relation to the baseline measurement the CO, heart rate, mean blood pressure will be measured before drug administration and at 3, 6, 10 and 15 min after drug administration

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ketamine, Fentanyl, Septic Shock

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ketamine group
Arm Type
Active Comparator
Arm Description
bolus of sedation for resuming sedation after sedation vacation
Arm Title
Fentanyl group
Arm Type
Active Comparator
Arm Description
bolus of sedation for resuming sedation after sedation vacation
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
Primary Outcome Measure Information:
Title
6-minutes Delta CO%
Description
percentage of change at 6 min after drug administration in relation to the baseline measurement
Time Frame
at 6 minutes after drug administration
Secondary Outcome Measure Information:
Title
Delta CO%
Description
percentage of change at each time point after drug administration in relation to the baseline measurement
Time Frame
3, 6, 10 and 15 minutes after drug administration
Title
heart rate
Description
beat per minute
Time Frame
3, 6, 10 and 15 minutes after drug administration
Title
mean blood pressure
Description
mmHg
Time Frame
3, 6, 10 and 15 minutes after drug administration
Title
norepinephrine dose
Description
mcg/kg/min
Time Frame
3, 6, 10 and 15 minutes after drug administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (>18 years) patients. With septic shock on vasopressor therapy Mechanically ventilated Need for sedation Exclusion Criteria: Hemodynamic instability (MAP <65 mmHg) despite appropriate volume replacement and vasopressor therapy Noradrenaline infusion rate <0.05 mcg/kg/min Poor cardiac window on the ultrasound. Known allergy to study drugs Neurocritical patients with signs of increased intracranial tension
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maha Mostafa, M.D
Phone
01000365115
Ext
+2
Email
maha.mostafa@cu.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ahmed hasanin, MD
Organizational Affiliation
Cairo University Kasr Alainy Faculty of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ahmed Mohamed Hasanin
City
Cairo
ZIP/Postal Code
11432
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The datasets used during the current study will be available from the corresponding author on reasonable request.

Learn more about this trial

Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock

We'll reach out to this number within 24 hrs